"ALPHA (drug)"

Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: Results of a cohort study. We determined whether rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) can predict remission or severe disability in rheumatoid arthritis (RA) patients treated with anti-tumor necrosis factor (TNF) alpha drugs.We performed

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-alpha drugs for refractory Crohn's disease Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-alpha drugs for refractory Crohn's disease ..

and the public.This study was part of a larger project assessing people’s risk of drug side effects. The researchers have developed a similar tool to predict risk of side effects with thiopurine,  leflunomide, and anti-TNF alpha drugs (drugs that also dampen the immune response).  You may be interested to readThis is a summary of: Nakafero G, and others. Risk stratified monitoring for methotrexate toxicity

improvement. Our case underscores the broad spectrum of clinical manifestations associated with cartilage hypoplasia syndrome and adds new evidence to the potential therapeutic efficacy of anti-TNF-alpha drugs in its treatment.

. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease . Am J Gastroenterol 2013 ; 108 : 433 – 40 . Article Locations:Article Location 35. Weber-Schoendorfer C , Oppermann M , Wacker E , Bernard N , Beghin D , Cuppers-Maarschalkerweerd B , et al . Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective

monitoring. Anti-TNF-alpha drugs were uncommonly discontinued due to abnormal monitoring blood tests after the first year of treatment. Extending the duration between monitoring blood-tests was cost-effective. Our results produce evidence for specialist society guidance to reduce patient monitoring burden and healthcare costs.

Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single center study. Biosimilar anti-tumor necrosis factor (TNF)-alpha drugs are widely used in the treatment of psoriasis, but only few studies reported the long-term experience of the various biosimilar agents in the real world practice. A monocentric retrospective observational recorded during the study period. Our results support that biosimilar anti-TNF-alpha drugs are effective and well tolerated drugs for the long-term treatment of psoriasis.

of these drugs or there are contra-indications to conventional therapy.Patients for whom surgery is inappropriate.Anti-TNF-alpha drugs should only be prescribed by clinicians familiar with their use and with the management of patients with Crohn's disease. NICE also recommends that:Treatment should be started with the cheapest drug (this will vary depending on drug administration costs, the dose and product , disease activity and individual response should be taken into consideration.In Crohn's disease, treatment should be continued for 12 months or until treatment fails, whichever is the shorter. Loss of response to anti-TNF-alpha drugs is becoming an increasing clinical problem; the reason for this unknown.In psoriatic arthritis, treatment should be stopped after 12 weeks if there is no adequate response

versus natalizumab as third-line therapy for patients with moderate-to-severe Crohn’s disease, who had failed to respond to two anti-tumour necrosis factor alpha drugs. The authors concluded that trying certolizumab pegol was cost-effective. The cost-effectiveness methods were valid, but the clinical sources were weak. The authors’ conclusions appear to depend on the model assumptions

remission, after treatment initiation, or after treatment cessation. Sperm DNA Fragmentation Index [DFI], concentration, morphology, and motility were evaluated. Sex hormones and seminal plasma anti-TNF-alpha drug levels were measured. In patients with severe disease, progressive sperm motility was impaired and increased significantly [from 28.4% to 37.4%, p = 0.045] during remission initiation [12.8% versus 10.0%, p = 0.02]. All other semen parameters were unaffected by therapy. Anti-TNF-alpha drugs were excreted in negligible amounts in semen. Severe active IBD reduces progressive sperm motility and testosterone levels, but sperm DNA integrity is unaffected by active disease. Anti-TNF-alpha therapy does not impair sperm quality.

the longitudinal patterns of immunogenicity during 7 years of antitumor necrosis factor-alpha drug certolizumab pegol (CZP) treatment for moderate-to-severe Crohn's disease. PRECiSE 3 patients (n = 595) received open-label CZP 400 mg every 4 weeks up to 7 years. CZP-ADAb expression, plasma CZP concentration, Harvey-Bradshaw Index, C-reactive protein, and fecal calprotectin concentrations were measured multiple

in patients with MC. Oral mesalazine is not recommended in patients with collagenous colitis for the induction of clinical remission. The use of anti-TNF-alpha drugs (infliximab, adalimumab) is recommended for the induction of remission in severe cases of MC that fail to respond to corticosteroids or immunomodulators, as an alternative to colectomy. This is the first consensus paper on MC based on GRADE

." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related imagesRelated Studies * Trip Database * TrendMD Ontology: Anti-tumor necrosis factor alpha drug(C1562242) Concepts Pharmacologic Substance(T121 necrosis factor alpha agent, Anti-TNF drug, Anti-tumor necrosis factor alpha drug (product), Anti-tumor necrosis factor alpha drug, Anti-tumour necrosis factor alpha drug Spanish agente con anti-factor de necrosis tumoral alfa (sustancia), agente con FNT-alfa, agente con TNF-alfa, agente con anti-factor de necrosis tumoral alfa, factor de necrosis tumoral alfa (producto), factor de necrosis tumoral